Correlation of transcription factor Sp1 expression with clinical and pathological characteristics and prognosis of hepatocellular carcinoma
-
摘要:
目的 通过研究肝癌组织内转录因子Sp1的表达及其与肝癌患者临床病理特征及预后的关系，探讨转录因子Sp1作为肝癌预后预测指标的可行性。 方法 对98例根治性切除术的肝细胞肝癌肿瘤组织芯片进行免疫组化检测Sp1的表达情况，分析其与肝癌患者临床病理特征及预后之间的关系。 结果 免疫组化结果显示Sp1在肝癌组织中表达明显高于对应正常肝脏组织，在有微血管侵犯的患者中升高尤其明显。进一步分析显示Sp1表达与肝癌患者术后总体生存率呈负相关，而与肝癌患者术后复发率呈正相关。 结论 转录因子Sp1在肝癌中明显高表达，可作为肝癌患者预后的独立预测指标。 Abstract:Objective To explore the clinical significance of transcription factor Sp1 expression in hepatocellular carcinoma (HCC) and association between Sp1 expression and survival in HCC patients. Methods With the use of immunoreactivity, Sp1 expression and its correlation with other clinicopathological characteristics were examined in a tissue microarray that contains samples from 98 HCC patients. Results HCC tissues expressed markedly higher levels of Sp1 than did adjacent normal liver tissues. Sp1 expression was closely associated with microvascular invasion, which suggests that HCC with more microvascular invasion is prone to have increased Sp1 expression. Overexpression of Sp1 correlates with significantly shorter overall survival and higher recurrence rates in HCC patients after curative resection. Conclusion Transcription factor Sp1 may be an independent prognostic factor for both overall survival and cumulative recurrence rate. -
Key words:
- hepatocellular carcinoma /
- transcription factor Sp1 /
- prognostic factor /
- tissue chip
-
图 1 Kaplan-Meier生存曲线显示，Sp1表达升高的患者，OS（A）更短，复发率（B）更高
Figure 1. Kaplan-Meier survival curves showing patients with increased expression of Sp1 had shorter OS (A) and higher recurrence rate (B)
▶A:OS; B:Recurrence rate
表 1 Sp1表达与肝癌肝癌患者临床病理特征的关系 n（%）
Table 1. Relationship between Sp1 expression and clinicopathologic features of HCC in patients with HCC
表 2 患者总生存期和肿瘤复发的多因素回归分析
Table 2. Multiple regression analysis of factors of patients with overall survival and tumor recurrence
-
[1] Siegel R, Desantis C, Jemal A. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1):9-29. doi: 10.3322/caac.21208 [2] Tang ZY, Ye SL, Liu YK, et al. A decade's studies on metastasis of hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2004, 130(4): 187-196. doi: 10.1007/s00432-003-0511-1 [3] Briggs MR, Kadonaga JT, Bell SP, et al. Purification and biochemical haracterization of the promoter- specific transcription factor, Sp1[J]. Science, 1986, 234(1):47-52. https://www.ncbi.nlm.nih.gov/pubmed/3529394 [4] Ishibashi H, Nakagawa K, Onimaru M, et al. Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor beta1, and tissue factor and also cell growth and invasion activities[J]. Cancer Res, 2000, 60 (11):6531-6536. https://cancerres.aacrjournals.org/content/60/22/6531 [5] Wang L, Wei D, Huang S, et al. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer[J]. Clin Cancer Res, 2003, 9(10):6371-6380. http://cn.bing.com/academic/profile?id=e41f0b06c2a7eb5f322a5aa6b58669e8&encoded=0&v=paper_preview&mkt=zh-cn [6] Fuchs B, Inwards CY, Janknecht R. Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma[J]. Clin Cancer Res, 2004, 10(4):1344-1353. doi: 10.1158/1078-0432.CCR-03-0038 [7] 周尘飞, 计骏, 袁菲, 等.转移相关基因2在胃癌中的表达及其与核转录因子Sp1的相关性[J].中华肿瘤杂志, 2012, 34 (8):592-595. doi: 10.3760/cma.j.issn.0253-3766.2012.08.007Zhou CF, Ji J, Yuan F, et al. Expression of metastasis associated 1 family member 2 (MTA2) in gastric cancer and its relationship with transcription factor Sp1[J]. Zhonghua Zhong Liu Za Zhi, 2012, 34 (8):592-595. doi: 10.3760/cma.j.issn.0253-3766.2012.08.007 [8] Wang F, Ma YL, Zhang P, et al. SP1 mediates the link between methylation of the tumour suppressor miR-149 and outcome in colorectal cancer[J]. J Pathol, 2013, 229(1):12-24. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=e5d48ce14c41cdf0efa7fc18ee52ef84 [9] Sankpal UT, Maliakal P, Bose D, et al. Expression of specificity protein transcription factors in pancreatic cancer and their association in prognosis and therapy[J]. Curr Med Chem, 2012, 19(22): 3779-3786. doi: 10.2174/092986712801661077 [10] Bedolla RG, Gong J, Prihoda TJ, et al. Predictive value of Sp1/Sp3/ FLIP signature for prostate cancer recurrence[J]. PLoS One, 2012, 7 (9):e44917. doi: 10.1371/journal.pone.0044917 [11] Grande L, Bretones G, Rosa-Garrido M, et al. Transcription factors Sp1 and p73 control the expression of the proapoptotic protein NOXA in the response of testicular embryonal carcinoma cells to cisplatin[J]. J Biol Chem, 2012, 287(32):26495-26505. doi: 10.1074/jbc.M112.376319 [12] Chae JI, Jeon YJ, Shim JH. Downregulation of Sp1 is involved in honokiol-induced cell cycle arrest and apoptosis in human malignant pleural mesothelioma cells[J]. Oncol Rep, 2013, 29(6): 2318-2324. doi: 10.3892/or.2013.2353 [13] Barrasa JI, Olmo N, Santiago-Gómez A, et al. Histone deacetylase inhibitors upregulate MMP11 gene expression through Sp1/Smad complexes in human colon adenocarcinoma cells[J]. Biochim Biophys Acta, 2012, 1823(2):570-581. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=6210107b2e3dc20e6a75dcf78375d62c [14] Sankpal UT, Goodison S, Abdelrahim M, et al. Targeting Sp1 transcription factors in prostate cancer therapy[J]. Med Chem, 2011, 7 (5):518-525. doi: 10.2174/157340611796799203 [15] Wang F, Li Y, Zhou J, et al. miR-375 is down-regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1[J].Am J Pathol, 2011, 179(5): 2580-2588. doi: 10.1016/j.ajpath.2011.07.037 [16] Xu Y, Zhao F, Wang Z, et al. MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1[J]. Oncogene, 2012, 31(11):1398-1407. doi: 10.1038/onc.2011.340 [17] 潘奇, 王鲁, 孙惠川, 等.转录因子Sp1在肝癌细胞VEGF表达调控中的作用[J].中国临床医学, 2007, 14(4):487-490. doi: 10.3969/j.issn.1008-6358.2007.04.013Pan Q, Wang L, Sun HC, et al. transcription factor Sp1 is essential for expression of VEGF in hepatocellular carcinoma[J]. Chin Med J Chin, 2007, 14(4):487-490. doi: 10.3969/j.issn.1008-6358.2007.04.013 -
下载:
点击查看大图
图(1) / 表(2)
计量
- 文章访问数: 13
- HTML全文浏览量: 14
- PDF下载量: 0
- 被引次数: 0
